We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

New Genes in the Carcinogenesis of Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03261752
Recruitment Status : Unknown
Verified July 2018 by Mariana Anwar, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : August 25, 2017
Last Update Posted : July 26, 2018
Information provided by (Responsible Party):
Mariana Anwar, Assiut University

Brief Summary:
Colo rectal cancer is one of the greatest ,mutual malignancies worldwide ,accounting for an estimated 1.3 million new cases and >500,000 mortality ⁄ year . is the fourth leading cause of cancer-associated mortality worldwide with speedily ,cumulative ,occurrence rate in the worldwide

Condition or disease Intervention/treatment
Colo-rectal Cancer Diagnostic Test: blood sample

Detailed Description:

colo rectal cancer represents a global and local problem, as it is one of the commonest types of cancer all over the world. Globally, Colo rectal cancer in women (9.2% of diagnoses) it is the second most common cause of cancer . it is the third most common in men (10.0%). After lung, stomach, and liver cancer it is the fourth most common cause of cancer death.

Cancer is a multistep procedure resulting from an ongoing accretion of genetic and epigenetic fluctuations to the genome.

Spartin is a protein that in humans is encoded by the SPG20 gene. This protein may be involved in endosomal trafficking, microtubule dynamics, or both functions. Aberrant promoter methylation of genes is a common epigenetic alteration in colo rectal cancer .

This has stimulated the prospect to implement a dependable, reasonable and simple approach for Colo rectal detection . The SPG20 gene is situated in chromosome band 13q13.3; the SPG20 gene converts the spartin protein, which is a multi functional protein that has formerly been recognized to be complicated in intra cellular epidermal growth factor receptor trading , The serine-threonine kinase 31 (STK31) gene was initially identified through cDNA subtraction as a testis-specific protein kinase gene expressed in mouse spermatogonia . Recently, STK31 has been described as a novel cancer testis (CT) antigen, highly expressed in Gastrointestinal cancer cells (colo rectal, gastric and esophageal cancer), while restricted to testis and fetal brain in normal tissues .

It was found that SPG20 is mutated in Troy er syndrome, an hereditary spastic paraplegia

Layout table for study information
Study Type : Observational
Estimated Enrollment : 62 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Investigating the Role of SPG20,STK31 Genes in the Carcinogenesis of Colorectal Cancer
Estimated Study Start Date : October 1, 2018
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
patient with cancer
blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
Diagnostic Test: blood sample
Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.

healthy people
blood sample will be collected for comparison
Diagnostic Test: blood sample
Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.

Primary Outcome Measures :
  1. detection of SPG20&STK31 genes [ Time Frame: 5 months ]
    detection of SPG20&STK31 genes and prediction future treatment for colo-rectal cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
patient between 35-65 who are newly diagnosed with colorectal cancer

Inclusion Criteria:

  • age between 35-65
  • patient with colorectal cancer (at any stage)
  • both sex included

Exclusion Criteria:

  • pediatric patients
  • patient with insufficient data
  • cardiac patient
  • pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03261752

Layout table for location contacts
Contact: mariana anwar, M.st 01012944965 mariana.10@yahoo.com
Contact: Naglaa Idriss 01003830234 naglaaidriss@hotmail.com

Sponsors and Collaborators
Assiut University
Layout table for additonal information
Responsible Party: Mariana Anwar, Demonstrator of cancer biology, Assiut University
ClinicalTrials.gov Identifier: NCT03261752    
Other Study ID Numbers: CRC
First Posted: August 25, 2017    Key Record Dates
Last Update Posted: July 26, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplastic Processes
Pathologic Processes